About madrigal pharmaceuticals inc - MDGL
Madrigal Pharmaceuticals, Inc. engages in the development and commercialization of innovative therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product, MGL-3196, is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. The company was founded by Rebecca A. Taub, Frederick Bernard Craves, and Edward Chiang on March 10, 2000 and is headquartered in West Conshohocken, PA.
MDGL At a Glance
Madrigal Pharmaceuticals, Inc.
Four Tower Bridge
West Conshohocken, Pennsylvania 19428
| Phone | 1-267-824-2827 | Revenue | 958.40M | |
| Industry | Pharmaceuticals: Major | Net Income | -288,284,000.00 | |
| Sector | Health Technology | 2025 Sales Growth | 432.053% | |
| Fiscal Year-end | 12 / 2026 | Employees | 915 | |
| View SEC Filings |
MDGL Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 13.631 |
| Price to Book Ratio | 22.071 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -41.607 |
| Enterprise Value to Sales | 12.963 |
| Total Debt to Enterprise Value | 0.028 |
MDGL Efficiency
| Revenue/Employee | 1,047,434.973 |
| Income Per Employee | -315,064.481 |
| Receivables Turnover | 7.127 |
| Total Asset Turnover | 0.833 |
MDGL Liquidity
| Current Ratio | 4.015 |
| Quick Ratio | 3.774 |
| Cash Ratio | 3.186 |
MDGL Profitability
| Gross Margin | 93.984 |
| Operating Margin | -31.312 |
| Pretax Margin | -30.08 |
| Net Margin | -30.08 |
| Return on Assets | -25.048 |
| Return on Equity | -42.486 |
| Return on Total Capital | -30.335 |
| Return on Invested Capital | -31.64 |
MDGL Capital Structure
| Total Debt to Total Equity | 57.68 |
| Total Debt to Total Capital | 36.58 |
| Total Debt to Total Assets | 27.599 |
| Long-Term Debt to Equity | 57.511 |
| Long-Term Debt to Total Capital | 36.473 |